AI주식인사이트AI Stock Insight
C

네이처셀

007390KOSDAQ기초 의약물질 제조업

52.3 / 100

Reference Date: 2026-07-24

Financial Score18.5 / 40
News Sentiment16.8 / 25
Momentum10.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 7.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NatureCell focuses on developing and selling stem cell therapies (e.g., JointStem, AstroStem), stem cell culture media, cosmetics, and beverage R&D and sales. The company is expanding its global presence through clinical trials in the U.S. and Japan, as well as a 2022 acquisition of a U.S. subsidiary. In 2024, the stem cell business accounted for approximately 68% of total revenue.

Number of Employees

83people

Average Salary

45.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
—Industry Average 1.263.5Point
ROE
-4.45Industry Average -6.033.5Point

Below industry avg

Debt Ratio
4.76Industry Average 6.625.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲15.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼302.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.4% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 3Negative 1Average Sentiment Score 67.1

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 24,050Won52-week high 37,80052-week low 16,900
1-month return1.0Point

1m -7.14% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 1Negative 1
  • Neutral주요사항보고서(전환사채권발행결정)2026-07-22
  • Negative기타경영사항(자율공시) (조인트스템 품목허가 반려 처분 취소 청구소송 1심 판결 결과)2026-07-09